Your session is about to expire
← Back to Search
PRRT for Neuroendocrine Tumors (COMPOSE Trial)
COMPOSE Trial Summary
This trial will compare the effects of a new cancer treatment to the best existing cancer treatment.
COMPOSE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCOMPOSE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.COMPOSE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am allergic to Lutetium 177Lu or related substances.My GEP-NETs cancer is confirmed and can't be removed by surgery.I am 18 years old or older.I have had Peptide Receptor Radionuclide Therapy.I have not had major surgery in the last 4 weeks.I have a serious illness that is not cancer.I do not have kidney, liver, heart, or blood conditions that could affect my safety during the trial.My condition is positive for somatostatin receptors.I have no other cancer types besides the one being treated.
- Group 1: Peptide Receptor Radionuclide Therapy (PRRT) Arm
- Group 2: CAPTEM(Capecitabine-Temozolomide), Everolimus, FOLFOX(Folinic acid + Fluorouracil + Oxaliplatin)
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there many precedent cases for177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT?
"There are 1099 ongoing clinical trials investigating 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, with 297 trials in Phase 3. While most of the trials for 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT are located in Guangzhou, Guangdong, there are 38873 locations running studies for 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT."
Are there any vacancies in this research project for participants?
"That is correct, the listing on clinicaltrials.gov does show that this study is still looking for patients. The trial was originally posted on December 21th 2021 and was updated as recently as September 13th of this year. They are aiming to enroll a total of 202 individuals across 3 different research sites."
What has 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT been shown to be effective in treating?
"177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT can provide treatment for patients with progressive disease, rectal carcinoma, and lung cancer."
Is 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT an FDA-sanctioned treatment?
"There is both efficacy and safety data available from Phase 3 trials, which earned 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT a score of 3 on our Power scale."
How many individuals are included in this research project?
"That is correct. The website clinicaltrials.gov has the latest information on this trial, which was last updated on September 13th, 2022. The study is looking for 202 individuals from 3 different locations."
Share this study with friends
Copy Link
Messenger